A malaria vaccine developed by the University of Oxford and the Serum Institute of India prevented around three-quarters of symptomatic malaria cases in young children the.
More than 2 years after its controversial accelerated FDA approval, Biogen says it will halt development and commercialization of aducanumab and focus on lecanemab.